What ate the public biotech market?

The usual disclaimer: I’m not investment advice. I hold $XBI. With thanks to Carl West for editing and feedback. In case you don’t know, the biotech market is down. Like, really down. With the biotech rout in the public markets, I wondered whether there are any trends that can be pulled out of the plungeContinue reading “What ate the public biotech market?”